BioPharmSignal logoBioPharmSignal

Biotech News

Nkarta to Participate in September Investor Conferences

Nkarta (NKTX)NkartaCompany update

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences:

Related news

NKTXNkarta2026-09-08 11:00 EST

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

KYMRKymera2026-09-02 20:01 EST

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

RLAYRelay Therapeutics2026-09-01 20:46 EST

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

NRIXNurix Therapeutics2026-09-01 12:00 EST

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

KURAKura Oncology2026-09-01 11:15 EST

Kura Oncology to Participate in Three Investor Conferences in September

NKTXNkarta2026-08-10 20:24 EST

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

MMSIMerit Medical2026-09-04 13:25 EST

Merit Medical to Participate in Upcoming Investors Conferences in September

BMEABiomea Fusion2026-09-03 12:00 EST

Biomea Fusion to Participate in Upcoming Investor Conferences

ZNTLZentalis2026-09-02 20:05 EST

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

CHRSCoherus BioSciences, Inc.2026-08-31 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

View all latest news

Nkarta

Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer. NKX019 NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing. Ntrust Studies Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with...

Recent company news

NKTXNkarta2026-09-10 11:00 EST

Nkarta to Participate in September Investor Conferences

NKTXNkarta2026-09-08 11:00 EST

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

NKTXNkarta2026-08-10 20:24 EST

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

NKTXNkarta2026-05-12 20:01 EST

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

NKTXNkarta2026-04-15 20:01 EST

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Stock data

Close
2.83 USD
Market cap
208.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States